Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $37.48 USD
Change Today -0.25 / -0.66%
Volume 390.0
UCBJY On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa - unsponsored adr (UCBJY) Snapshot

Open
$37.48
Previous Close
$37.73
Day High
$37.48
Day Low
$37.48
52 Week High
09/2/14 - $47.85
52 Week Low
05/26/15 - $34.10
Market Cap
14.6B
Average Volume 10 Days
377.6
EPS TTM
--
Shares Outstanding
389.0M
EX-Date
04/30/15
P/E TM
--
Dividend
$0.59
Dividend Yield
1.58%
Current Stock Chart for UCB SA - UNSPONSORED ADR (UCBJY)

Related News

No related news articles were found.

ucb sa - unsponsored adr (UCBJY) Related Businessweek News

No Related Businessweek News Found

ucb sa - unsponsored adr (UCBJY) Details

UCB S.A., a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s product pipeline includes brivaracetam as an adjunctive therapy for epilepsy POS; Vimpat for various types of epilepsy; UCB4942 for drug resistant epilepsy; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 for immune-inflammatory diseases; UCB7665 for immunological diseases; and dapirolizumab pegol for systemic lupus erythematosus. The company has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,535 Employees
Last Reported Date: 02/28/15
Founded in 1928

ucb sa - unsponsored adr (UCBJY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa - unsponsored adr (UCBJY) Key Developments

Amgen and UCB Announce Positive Top-Line Results from Open-Label Phase 3 Study of Romosozumab Compared with Teriparatide

Amgen and UCB announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy). The study (NCT01796301) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of total hip bone mineral density (measured by DXA) through month 12. STRUCTURE was a Phase 3, multi-center, international, randomized, open-label, teriparatide-controlled study that evaluated safety, tolerability and efficacy of romosozumab in women with postmenopausal osteoporosis. A total of 436 patients previously treated with bisphosphonate therapy received either subcutaneous romosozumab (210 mg monthly) or subcutaneous teriparatide (20 mcg daily) through to month 12. The overall subject incidence of adverse events was generally balanced between arms. Adverse events in patients treated with romosozumab were similar to those previously reported and no new safety signals were detected. Adverse events reported in the romosozumab arm in more than 5% of patients were nasopharyngitis, arthralgia, back pain, headache and fall.

Cipla Reportedly Mulls Acquisition Of Stake In Kremers

Cipla Limited (NSEI:CIPLA) reportedly seeking acquisition of stakes in Kremers Urban Pharmaceuticals Inc. from UCB S.A. (ENXTBR:UCB). Cipla has emerged as the sole Indian contender for Kremers Urban Pharmaceuticals Inc. which is pegged at around $1.3 billion. "Cipla is the only Indian bidder for KU but it is pitted against a few powerful private equity players. It also depends on whether Cipla is prepared to shell out a large amount in a single bid," an industry watcher told Economic Times. Lupin Limited (BSE:500257) and Torrent Pharmaceuticals Ltd. (BSE:500420) were named as the other two Indian parties that had initially shown interest but eventually opted out. One of them is China's conglomerate China Grand Group. UCB floated the divestiture of Kremers Urban in 2014. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. Kremers had sales of $463 million in 2014.

UCB Reports Revenue Results for the First Half of 2015: Provides Earnings Guidance for the Year 2015

UCB reported earnings results for the first half of 2015. For the period, the company reported 21% year-on-year rise in revenues to EUR 1.917 billion. The revenues were mainly driven by the better-than-expected sales performance of the company's core products. The company is now forecasting total revenues to reach between EUR 3.65 billion and EUR 3.75 billion. This compares to a previous full-year revenues forecast of between EUR 3.55 billion and EUR 3.65 billion in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCBJY:US $37.48 USD -0.25

UCBJY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.130.70 CHF +1.80
Endo International PLC $73.48 USD -3.52
Grifols SA €36.21 EUR +0.095
Hospira Inc $89.96 USD -0.01
Sigma-Aldrich Corp $139.44 USD +0.03
View Industry Companies
 

Industry Analysis

UCBJY

Industry Average

Valuation UCBJY Industry Range
Price/Earnings 48.5x
Price/Sales 3.6x
Price/Book 2.4x
Price/Cash Flow 39.0x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA - UNSPONSORED ADR, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.